GW Pharma (GWPH) Posts Q2 Loss of 5c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Leerink Partners Maintains Bullish View on GW Pharma (GWPH) Posts Q2
May 11, 2015 11:06 AM EDTLeerink Partners analyst Paul Matteis reiterated an Outperform rating and $135 price target on GW Pharma (NASDAQ: GWPH) after the company reported F2Q15 EPS of (£0.03) pounds, which was slightly better than our estimate of (£0.07) pounds.
Matteis notes the first phase III Epidiolex study in Dravet... More
